Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO -0.49%91 3-Year EBITDA Growth Rate is 27.30% as of Jun. 2026, which is 600% above its 10-year median of 3.90. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $98.78 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,128 Biotechnology companies, Halozyme Therapeutics ranks better than 63.65% on this metric.
During the past 12 months, Halozyme Therapeutics's average EBITDA Per Share Growth Rate was -5.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 36.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Halozyme Therapeutics was 46.10% per year. The lowest was -97.20% per year. And the median was 3.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Halozyme Therapeutics 3-Year EBITDA Growth Rate Related Terms
HALO vs ARWR, CORT, MDGL: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.30% mean?
Halozyme Therapeutics (HALO) has a 3-Year EBITDA Growth Rate of 27.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Halozyme Therapeutics and its competitors. This is 600% above median its historical median of 3.90. According to the industry distribution chart, Halozyme Therapeutics ranks #410 out of 1128 companies in the Biotechnology industry, placing it in the top 36.3%.
Is Halozyme Therapeutics' 3-Year EBITDA Growth Rate too high?
Halozyme Therapeutics' current 3-Year EBITDA Growth Rate of 27.30% is 600% above median its 10-year median of 3.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Halozyme Therapeutics' value of 27.30% is 86.3% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #410 out of 1128 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' 3-Year EBITDA Growth Rate compare to ARWR and CORT?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #410 out of 1128 companies for 3-Year EBITDA Growth Rate. This puts Halozyme Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Halozyme Therapeutics' value of 27.30% is 86.3% above this benchmark. While the company's 10-year median is 3.90 vs. the industry median of 14.65, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current 3-Year EBITDA Growth Rate of 27.30% is 86.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current 3-Year EBITDA Growth Rate is 27.30%, which is 600% above median its own 10-year median of 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Overvalued. The stock's GF Value™ is $98.78, compared to a current price of $110.24 — trading 11.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 27.30%, which is 600% above median its 10-year median of 3.90 and 86.3% above the Biotechnology industry median of 14.65. Halozyme Therapeutics' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current 3-Year EBITDA Growth Rate is 27.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of $110.24 is trading 11.6% above its estimated GF Value™ of $98.78.
GuruFocus considers Halozyme Therapeutics to be Modestly Overvalued.
Key valuation signals for HALO:
3-Year EBITDA Growth Rate: 27.30% (600% above median its 10-year median of 3.90)
GF Value™: $98.78 vs. price of $110.24 (11.6% above fair value)
Industry Position: 86.3% above the Biotechnology median (#410 of 1128)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score
Get the complete analysis for HALO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
